Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando A Bozza

Showing results (181-190 of 202) with videos related to

Pageof 21
Sort By:
Intensive Care Medicine|October 10, 2019
ICU staffing feature phenotypes and their relationship with patients' outcomes: an unsupervised machine learning analysisFernando G Zampieri, Jorge I F Salluh, Luciano C P Azevedo, et al.
JHEP Reports : Innovation in Hepatology|January 31, 2024
Prevention of lipid droplet accumulation by DGAT1 inhibition ameliorates sepsis-induced liver injury and inflammationLívia Teixeira, Filipe S Pereira-Dutra, Patrícia A Reis, et al.
Brain, Behavior, & Immunity - Health|July 18, 2024
Changes in neuroinflammatory biomarkers correlate with disease severity and neuroimaging alterations in patients with COVID-19 neurological complicationsFernanda G Q Barros-Aragão, Talita P Pinto, Victor C Carregari, et al.
Plos Pathogens|December 16, 2020
Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediatorsSuelen Silva Gomes Dias, Vinicius Cardoso Soares, André C Ferreira, et al.
Antimicrobial Agents and Chemotherapy|November 21, 2018
Beyond Members of the <i>Flaviviridae</i> Family, Sofosbuvir Also Inhibits Chikungunya Virus ReplicationAndré C Ferreira, Patrícia A Reis, Caroline S de Freitas, et al.
Plos Neglected Tropical Diseases|January 31, 2019
Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivoCaroline S de Freitas, Luiza M Higa, Carolina Q Sacramento, et al.
Scientific Reports|January 19, 2017
The clinically approved antiviral drug sofosbuvir inhibits Zika virus replicationCarolina Q Sacramento, Gabrielle R de Melo, Caroline S de Freitas, et al.
Microbiome|April 23, 2022
Human endogenous retrovirus K in the respiratory tract is associated with COVID-19 physiopathologyJairo R Temerozo, Natalia Fintelman-Rodrigues, Monique Cristina Dos Santos, et al.
Frontiers in Immunology|March 7, 2022
Simvastatin Downregulates the SARS-CoV-2-Induced Inflammatory Response and Impairs Viral Infection Through Disruption of Lipid RaftsLívia Teixeira, Jairo R Temerozo, Filipe S Pereira-Dutra, et al.
Scientific Reports|April 25, 2017
Corrigendum: The clinically approved antiviral drug sofosbuvir inhibits Zika virus replicationCarolina Q Sacramento, Gabrielle R de Melo, Caroline S de Freitas, et al.
Pageof 21

Showing results (181-190 of 202) with videos related to

Sort By:
Pageof 21
Intensive Care Medicine|October 10, 2019
ICU staffing feature phenotypes and their relationship with patients' outcomes: an unsupervised machine learning analysisFernando G Zampieri, Jorge I F Salluh, Luciano C P Azevedo, et al.
JHEP Reports : Innovation in Hepatology|January 31, 2024
Prevention of lipid droplet accumulation by DGAT1 inhibition ameliorates sepsis-induced liver injury and inflammationLívia Teixeira, Filipe S Pereira-Dutra, Patrícia A Reis, et al.
Brain, Behavior, & Immunity - Health|July 18, 2024
Changes in neuroinflammatory biomarkers correlate with disease severity and neuroimaging alterations in patients with COVID-19 neurological complicationsFernanda G Q Barros-Aragão, Talita P Pinto, Victor C Carregari, et al.
Plos Pathogens|December 16, 2020
Lipid droplets fuel SARS-CoV-2 replication and production of inflammatory mediatorsSuelen Silva Gomes Dias, Vinicius Cardoso Soares, André C Ferreira, et al.
Antimicrobial Agents and Chemotherapy|November 21, 2018
Beyond Members of the <i>Flaviviridae</i> Family, Sofosbuvir Also Inhibits Chikungunya Virus ReplicationAndré C Ferreira, Patrícia A Reis, Caroline S de Freitas, et al.
Plos Neglected Tropical Diseases|January 31, 2019
Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivoCaroline S de Freitas, Luiza M Higa, Carolina Q Sacramento, et al.
Scientific Reports|January 19, 2017
The clinically approved antiviral drug sofosbuvir inhibits Zika virus replicationCarolina Q Sacramento, Gabrielle R de Melo, Caroline S de Freitas, et al.
Microbiome|April 23, 2022
Human endogenous retrovirus K in the respiratory tract is associated with COVID-19 physiopathologyJairo R Temerozo, Natalia Fintelman-Rodrigues, Monique Cristina Dos Santos, et al.
Frontiers in Immunology|March 7, 2022
Simvastatin Downregulates the SARS-CoV-2-Induced Inflammatory Response and Impairs Viral Infection Through Disruption of Lipid RaftsLívia Teixeira, Jairo R Temerozo, Filipe S Pereira-Dutra, et al.
Scientific Reports|April 25, 2017
Corrigendum: The clinically approved antiviral drug sofosbuvir inhibits Zika virus replicationCarolina Q Sacramento, Gabrielle R de Melo, Caroline S de Freitas, et al.
Pageof 21